The in vivo activity of the Keggin polyoxotungstate PM-19 [K7(PTi2W10O40)·6H2O] was investigated against herpes simplex virus type 2 (HSV-2) in ddY mice. A single dose of PM-19 at 100mg kg−1administered intraperitoneally (i.p.) immediately after i.p. infection of ddY mice with HSV-2 offered 92% protection against an otherwise lethal HSV-2 infection. PM-19 was less or not effective if given by any route other than the i.p. route. When repeated doses of PM-19 were administered i.p. on day 0 (immediately after infection) and day 1 and 2 after infection, it proved protective over a dosage range of 0.1-50 mg kg−1day−1, its ED50 (50% effective dose, based on the number of survivors) being 0.25 mg kg−1day−1. Under these conditions, ACV was not effective even at doses up to 100 mg kg−1day−1.
References
1.
AblashiD.V.TwardzikD.R.EastonJ.M.ArmstrongG.R.LuetzelerJ.JasminC., and ChermannJ.-C. (1977) Effects of 5-tungsto-2-antimoniate in oncogenic DNA and RNA virus-cell systems. Eur J Cancer13: 713–720.
2.
BallardiniR.ChiorboliE., and BalzaniV. (1984) Phytophysical properties of Eu(Siw11O39)213– and Eu(BW11O39)215–. Inorg Chim Acta95: 323–327.
3.
CoenM.D., and SchafferP.A. (1980) Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci, USA77: 2265–2269.
4.
De ClercqE. (1991) Therapy for herpesvirus infections. Curr Opinion Infect Dis4: 795–803.
5.
FieldH.J.DarbyG., and WildyP. (1980) Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol49: 115–124.
6.
FischerJ.RicardL., and WeissR. (1976) The structure of the heteropolytungstate (NH4)17Na[NaW21Sb9O86]-14H2O. An inorganic cryptate. J Am Chem Soc98: 3050–3052.
7.
FukumaM.SetoY., and YamaseT. (1991) In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus. Antiviral Res16: 327–339.
8.
IkedaS.NeytsJ.YamamotoN.MurrerB.TheobaldB.BossardG.HensonG.AbramsM.PickerD., and De ClercqE. (1993a) In vitro activity of a novel series of polyoxosilicotungstates against human myxo-, herpes- and retrovirus. Antiviral Chem Chemother4: 253–262.
9.
IkedaS.NishiyaS.YamamotoA.YamaseT.NishimuraC., and De ClercqE. (1993b) Activity of the Keggin polyoxotungstate PM-19 against herpes simplex virus type 2 infection in immunosuppressed mice: role of peritoneal macrophage activation. J Med Virol, in press.
10.
InoueY.TakeY.TokutakeY.YoshidaT.YamamotoA.YamaseT., and NakamuraS. (1990) Inhibition of replication of human immunodeficiency virus by a heteropolyoxotungstate (PM-19). Chem Pharm Bull38: 285–287.
11.
JasminC.RaynaudN.ChermannJ.-C.HaapalaD.SinoussiF.Boy-LoustauC.BonissolC.KonaP., and RaynaudM. (1973) In vitro effects of silicotungstate on some RNA viruses. Biomedicine18: 319–327.
12.
JasminC.ChermannH.C.HerveG.TezeA.SouchayA.Boy-LoustauC.RaybaudN.SinoussiF., and RaynaudM. (1974) In vivo inhibition of murine leukemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimoniate. J Natl Cancer Inst53: 469–474.
MachidaH.AbiruT., and IkedaT. (1985) Selective anti-herpes activity of BV-araU. In: IshigamiJ. (ed.), Recent Advances in Chemotherapy, pp. 1959–1960. University of Tokyo Press, Tokyo.
15.
MachidaH.IkedaT., and AshidaN. (1990) Comparison of antiviral efficacies of 1-β-D-arabinofuranosyl-E-5-(2-bromovi-nyl)uracil (brovavir) and acyclovir against herpes simplex virus type 1 infections in mice. Antiviral Res14: 99–108.
16.
MorahanP.S. (1984) Interactions and herpesviruses with mononuclear phagocytes. In: RouseB.T., and LopezC. (eds), Immunobiology of Herpes Simplex Virus Infection, pp. 71–89. CRC Press, FL.
17.
SchinaziR.F.PetersJ.SokolM.K., and NahmiasA.J. (1983) Therapeutic activities of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrob Agents Chemother24: 95–103.
18.
SchnipperL.E., and CrumpackerC.S. (1980) Resistance of herpes simplex virus to acycloguanosine: the role of the viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci, USA77: 2270–2273.
19.
SmeeD.F.CampbellN.L., and MatthewsT.R. (1985) Comparative anti-herpes activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2′-fluoropyrimidine nucleosides. Antiviral Res5: 259–267.
20.
TakeY.TokutakeY.InoueY.YoshidaT.YamamotoA.YamaseT., and NakamuraS. (1991) Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro. Antiviral Res15: 113–124.
21.
TerryB.J.MazinaK.E.TuomariA.V.HaffeyM.L.HagenM.FieldmanA.SlusarchykW.A.YoungM.G.ZahlerR., and FieldA.K. (1988) Broad spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG. Antiviral Res10: 235–252.
22.
WinklerI.WinkelmannE.SchollT.RösnerM.JahneG., and HeisbergM. (1990) Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models. Antiviral Res14: 61–74.
23.
YamamotoN.ScholsD.De ClercqE.DebyserZ.PauwelsR.BalzariniJ.NakashimaH.BabaM.HosoyaM.SnoeckR.NeytsJ.AndreiG.MurrerB.TheobaldB.BossardG.HensonG.AbramsM., and PickerD. (1992) Mechanisms of anti-HIV action of polyoxometalates, a class of broad-spectrum antiviral agents. Mol Pharmacol42: 1109–1117.
24.
YamaseT., and WatanabeR. (1986) Photoredox chemistry of Keggin dodecatungstoborate [BW12O40]5– and role of heterogenous catalysis in hydrogen formation. J Chem Soc Perkin Trans1669–1675.
